Endpoint

Aspartate aminotransferase

Enzymes of the transferase class that catalyze the conversion of L-aspartate and 2-ketoglutarate to oxaloacetate and L-glutamate. EC 2.6.1.1.

Definition from MeSH (D001219), National Library of Medicine, read 2026-09-16. NLM revises MeSH; this copy may not reflect its current record.

CAT:outcome/aspartate-aminotransferasereported in U/L25 findings from 12 compounds

Open in the graph

What moved it

How to read these marks

25 findings · 12 compounds · 7 null · by evidence strength

Compound	Direction	Findings	Strongest evidence
curcumin	down 7 · no effect 1	8	Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
berberine	no effect 2 · down 1	3	Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
empagliflozin	no effect 1 · down 1	2	Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
NMN zwitterion	no effect	1	Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
piperine	down	1	Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
resveratrol	no effect	1	Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
α-tocopherol	down	1	Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
L-glutamine	down 1 · no effect 1	2	Evidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.
astaxanthin	down	3	Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.
Lactobacillus acidophilus	down	1	Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.
Moringa oleifera	down	1	Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.
sodium benzoate	up	1	Evidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited.

Reported to move it

18 findings

α-tocopherol — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding
“Vitamin E likely slightly reduces serum alanine transaminase (ALT) (MD -9.29, 95% CI -13.69 to -4.89; 11 trials, 708 participants; moderate certainty evidence) and aspartate aminotransferase (AST) (MD -4.90, 95% CI -7.24 to -2.57; 11 trials, 695 participants; moderate certainty evidence) levels compared with placebo or no intervention.”
Quoted verbatim from Vitamin E for people with non-alcoholic fatty liver disease..
Study

meta-analysis
Participants

695
Population

People with non-alcoholic fatty liver disease (children and adults); vitamin E alone versus placebo or no intervention; 13 of 16 trials included lifestyle or low-calorie diet co-interventions
Effect -4.9 mean difference, 95% CI -7.24 to -2.57
Vitamin E for people with non-alcoholic fatty liver disease.2024PMID:39412049Permalink
curcumin — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×6
“The overall pooling of data indicated that curcumin supplementation was significantly associated with reduced AST with MD (95% CI) of −3.90 (−5.97, −1.82) units/L, although high heterogeneity was observed (I2 = 73.9%).”
Quoted verbatim from An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand..
Study

meta-analysis
Dose

80–3000 mg/day pooled across bioavailability-enhanced forms (80–1000 mg/day), curcumin extracts (1500 mg/day) and turmeric powder (2000–3000 mg/day)
Population

Adults with MAFLD (NAFLD/NASH); overall pooling of 15 RCTs, all curcumin forms; liver enzymes were a primary outcome of interest
Effect -3.9 mean difference, 95% CI -5.97 to -1.82
An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.2023PMID:37037891Permalink
curcumin — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×6
“The results showed that curcumin reduced AST compared with placebo [SMD = -0.48, 95% CI (-0.76, -0.20), P = 0.0007].”
Quoted verbatim from Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis..
Study

meta-analysis
Participants

681
Population

adults with non-alcoholic fatty liver disease
Effect -0.48 standardised mean difference, 95% CI -0.76 to -0.2
Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.2022PMID:36159792Permalink
curcumin — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×6
“Similarly, the mean AST reduction was − 15.03 ± 16.31 U/L in the nanocurcumin group and − 0.92 ± 11.64 U/L in the placebo group, with a significant between-group difference ( P = 0.004).”
Quoted verbatim from Effect of nano-curcumin supplementation on liver fibrosis in patients with NAFLD-associated fibrosis: a double-blind randomized controlled trial..
Study

RCT
Dose

Oral nanomicellar curcumin (nano-curcumin, Exir Nano Sina), one 40 mg capsule twice daily with a main meal (80 mg/day) for 16 weeks
Population

Adults aged 30-70 y with NAFLD-associated liver fibrosis of METAVIR stage F2 or higher, Tehran, Iran; 55 randomised and all 55 analysed with no withdrawals (27 nano-curcumin, 28 placebo); secondary endpoint (declared primary outcomes: liver fibrosis and steatosis by FibroScan and the FIB-4 index); unadjusted between-group comparison of change from baseline; baseline AST was higher in the nano-curcumin arm than in the placebo arm (38.44 vs 27.21 U/L, P = 0.05); serum AST by enzyme colorimetric method on a Cobas c 311 analyser
Effect of nano-curcumin supplementation on liver fibrosis in patients with NAFLD-associated fibrosis: a double-blind randomized controlled trial.2025PMID:41168313Industry fundedPermalink
piperine — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding
“After the trial interval, concentrations of ALT and AST in the case group were statistically decreased compared with the control group with a P value < 0.001 and a P value of 0.002, respectively.”
Quoted verbatim from The impact of piperine on the metabolic conditions of patients with NAFLD and early cirrhosis: a randomized double-blind controlled trial..
Study

RCT
Duration

3 months
Dose

5 mg piperine capsule daily
Population

Adults with ultrasound grade 2-3 NAFLD and raised ALT, Iran
The impact of piperine on the metabolic conditions of patients with NAFLD and early cirrhosis: a randomized double-blind controlled trial.2024PMID:38200253Permalink
L-glutamine — decreases
LimitedEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.Finding
“The meta-analysis results showed that Gln supplementation was more effective in reducing AST level (MD = −21.45, 95% CI: −34.74 to −8.16, P = 0.002; Figure 7).”
Quoted verbatim from Efficacy of Glutamine in Treating Severe Acute Pancreatitis: A Systematic Review and Meta-Analysis..
Study

meta-analysis
Population

Severe acute pancreatitis patients, pooled across parenteral and enteral glutamine-supplemented nutrition trials
Effect -21.45 mean difference, 95% CI -34.74 to -8.16
Efficacy of Glutamine in Treating Severe Acute Pancreatitis: A Systematic Review and Meta-Analysis.2022PMID:35774540Permalink

Show the remaining 12

empagliflozin — decreases
LimitedEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.Finding
“Meta-analysis concluded that empagliflozin was able to decrease AST levels among patients suffering from NAFLD compared with controls; the statistical difference was significant (MD: −3.10, 95% CI: −6.18 to −0.02, p = 0.05, I2 = 0%).”
Quoted verbatim from Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis..
Study

meta-analysis
Population

Patients with NAFLD, pooled across randomized trials of empagliflozin 20 to 24 weeks; control arms were mostly placebo with one glimepiride arm
Effect -3.1 mean difference, 95% CI -6.18 to -0.02
Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.2022PMID:35282455Permalink
Moringa oleifera — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding
“The group treated with Moringa showed reduction in AST and ALT levels compared to HF group, though significant reduction in AST levels was seen in the HF + MO group against the HF group (68.80 U/L ± 4.26 vs. 146.3 U/L ± 8.84 U/L; p < 0.05; Figure 2A).”
Quoted verbatim from Moringa oleifera Improves MAFLD by Inducing Epigenetic Modifications..
Study

animal · not in humans
Duration

8 weeks
Dose

150 uL of 62.5 mg/mL extract daily by orogastric cannula, calculated as 290 mg/kg
Population

Male C57BL/6J mice fed a high-fat diet with high-sugar drinking water for 16 weeks (NASH model); extract given for the final 8 weeks, compared with untreated high-fat-diet mice
Moringa oleifera Improves MAFLD by Inducing Epigenetic Modifications.2022PMID:36296907Permalink
curcumin — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×6
“There were also significant reductions in body mass index and serum levels of total cholesterol, low-density lipoprotein cholesterol, triglycerides, aspartate aminotransferase, alanine aminotransferase, glucose, and glycated hemoglobin compared with the placebo group.”
Quoted verbatim from Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial..
Study

RCT
Duration

8 weeks
Dose

amorphous dispersion curcumin formulation 500 mg/day (~70 mg curcumin) for 8 weeks
Population

adults with ultrasound-diagnosed nonalcoholic fatty liver disease
Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial.2016PMID:27270872Permalink
curcumin — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×6
“Curcumin supplementation significantly reduced ALT (weighted mean difference [WMD], -4.10, 95%CI, -7.16 to -1.04) and AST (WMD, -3.27; 95%CI, -5.16 to -1.39), but not ALP (WMD, -0.49; 95%CI, -1.79 to 0.82).”
Quoted verbatim from Curcumin supplementation effect on liver enzymes in patients with nonalcoholic fatty liver disease: a GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials..
Study

meta-analysis
Population

patients with nonalcoholic fatty liver disease
Curcumin supplementation effect on liver enzymes in patients with nonalcoholic fatty liver disease: a GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials.2025PMID:38213188Permalink
curcumin — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×6
“Our results indicate that curcumin did not affect serum alanine aminotransferase, but it did reduce aspartate aminotransferase levels.”
Quoted verbatim from Does curcumin improve liver enzymes levels in nonalcoholic fatty liver disease? A systematic review, meta-analysis, and meta-regression..
Study

meta-analysis
Population

patients with non-alcoholic fatty liver disease (NAFLD)
Does curcumin improve liver enzymes levels in nonalcoholic fatty liver disease? A systematic review, meta-analysis, and meta-regression.2024PMID:38965866Permalink
astaxanthin — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×2
“In addition, the levels of AST and ALT were elevated, and were effectively reduced in the ASTX group compared with the IR group.”
Quoted verbatim from Astaxanthin prevents ischemia-reperfusion injury of the steatotic liver in mice..
Study

animal · not in humans
Duration

2 days
Dose

25 mg/kg by oral gavage three times, at 48 h, 24 h and 40 min before ischemia
Population

Male C57BL/6 mice with diet-induced steatotic liver (methionine- and choline-deficient high-fat diet, 21 days), 15 min ischemia and 3 h reperfusion; ASTX versus olive oil by gavage before ischemia-reperfusion
Astaxanthin prevents ischemia-reperfusion injury of the steatotic liver in mice.2017PMID:29121675Permalink
Lactobacillus acidophilus — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding
“Compared with the sham group, serum ALT, AST, TBA, ALP, TBIL, and liver index were significantly increased in the BDL group, while L. acidophilus treatment significantly reduced (, Supplementary Figure 4a-c), which is consistently with Mdr2−/− mice (Supplementary Figure 5a-d).”
Quoted verbatim from Lactobacillus acidophilus ameliorates cholestatic liver injury through inhibiting bile acid synthesis and promoting bile acid excretion..
Study

animal · not in humans
Duration

9 days
Dose

live L. acidophilus 10^8 CFU in 200 microlitres per day by oral gavage for 9 days after bile duct ligation
Population

Male C57BL/6J mice with bile-duct-ligation cholestatic liver injury (n = 5 to 6 per group); L. acidophilus versus BDL without treatment
Lactobacillus acidophilus ameliorates cholestatic liver injury through inhibiting bile acid synthesis and promoting bile acid excretion.2024PMID:39205654Permalink
astaxanthin — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×2
“Following ASX treatment (30 mg/kg or 60 mg/kg), ALT and AST decreased in a dose-dependent manner.”
Quoted verbatim from Astaxanthin Pretreatment Attenuates Hepatic Ischemia Reperfusion-Induced Apoptosis and Autophagy via the ROS/MAPK Pathway in Mice..
Study

animal · not in humans
Duration

14 days
Dose

30 mg/kg or 60 mg/kg for 14 days before ischemia reperfusion
Population

Mice with hepatic ischemia reperfusion injury, pretreated with astaxanthin 30 or 60 mg/kg for 14 days, compared with the untreated ischemia reperfusion group
Astaxanthin Pretreatment Attenuates Hepatic Ischemia Reperfusion-Induced Apoptosis and Autophagy via the ROS/MAPK Pathway in Mice.2015PMID:26023842Permalink
astaxanthin — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×2
“Serum levels of aspartate transaminase (AST) and alanine transaminase (ALT) were higher in ethanol-fed mice than pair-fed mice, but these values were decreased in ethanol with AXT-fed mice.”
Quoted verbatim from Astaxanthin alleviated ethanol-induced liver injury by inhibition of oxidative stress and inflammatory responses via blocking of STAT3 activity..
Study

animal · not in humans
Duration

10 days
Dose

0.2, 2 or 20 mg/kg daily by oral gavage in olive oil
Population

Male C57BL/6 mice (n = 8 per group) on a chronic-plus-binge ethanol model; AXT 0.2, 2 or 20 mg/kg by oral gavage for 10 days versus ethanol-fed mice without AXT
Astaxanthin alleviated ethanol-induced liver injury by inhibition of oxidative stress and inflammatory responses via blocking of STAT3 activity.2018PMID:30237578Permalink
curcumin — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×6
“The results showed that curcumin consumption can significantly reduce AST (-0.35, (-0.57 to -0.14)), total cholesterol (-0.81, (-1.34 to -0.27)), TG (-0.49, (-0.71 to -0.27)), and FBS (-0.28, (-0.46 to -0.09)) in patients with NAFLD.”
Quoted verbatim from The Effects of Curcumin Supplementation on Metabolic Biomarkers and Body Mass Index in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials..
Study

meta-analysis
Population

adults with NAFLD, meta-analysis of 14 RCTs
The Effects of Curcumin Supplementation on Metabolic Biomarkers and Body Mass Index in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials.2022PMID:35345991Permalink
sodium benzoate — increases
InsufficientEvidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited.Finding
“Administration of SB to rats with hepatocyte injury exacerbated liver damage with a significant increase in the activities of serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP).”
Quoted verbatim from Sodium benzoate exacerbates hepatic oxidative stress and inflammation in lipopolysaccharide-induced liver injury in rats..
Study

animal · not in humans
Duration

14 days
Dose

600 mg/kg, oral, 14 days
Population

rats with LPS-induced (0.25 mg/kg) hepatocyte injury given sodium benzoate 600 mg/kg orally for 14 days; LPS background present in both compared arms
Sodium benzoate exacerbates hepatic oxidative stress and inflammation in lipopolysaccharide-induced liver injury in rats.2023PMID:36927185Permalink
berberine — decreases
InsufficientEvidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited.Finding
“However, oral administration of BBR not only reversed hepatocyte necrosis, but also decreased the elevated levels of TBA, ALP, TBIL, DBIL, ALT, and AST ( Supplementary Fig. 1A, 1B).”
Quoted verbatim from Gut microbiota-mediated berberine metabolism ameliorates cholestatic liver disease by suppressing 5-hydroxytryptamine production..
Study

animal · not in humans
Duration

7 days
Population

C57BL/6J mice with bile duct ligation-induced cholestatic liver injury; serum AST by automated biochemical analyser
Gut microbiota-mediated berberine metabolism ameliorates cholestatic liver disease by suppressing 5-hydroxytryptamine production.2026PMID:41087029Permalink

Measured, no effect detected

7 findings

empagliflozin — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result
“In comparison with control group for non-alcoholic fatty liver disease, empagliflozin treatment shows no substantial impact on ALT (SMD=-0.09; 95% CI=-0.37 to 0.18; P=0.50; Figure 4), AST (SMD=-0.26; 95% CI=-0.53 to 0.02; P=0.07; Figure 5), LDL (SMD=-0.31; 95% CI=-0.74 to 0.11; P=0.15; Figure 6) or TG (SMD=-0.17; 95% CI=-0.54 to 0.19; P=0.35; Figure 7).”
Quoted verbatim from Empagliflozin for the treatment of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials..
Study

meta-analysis
Dose

10 mg daily
Population

Patients with non-alcoholic fatty liver disease, pooled across randomized trials of empagliflozin 10 mg daily versus placebo
Effect -0.26 standardised mean difference, 95% CI -0.53 to 0.02
Empagliflozin for the treatment of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.2022PMID:36910362Permalink
resveratrol — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result
“Interestingly, the result suggested that there was no significant efficacy of resveratrol on ALT level in NAFLD patients [SMD = −0.16, 95% CI (−0.67, 0.35), p = 0.542], nor was the efficacy in AST [SMD = −0.39, 95% CI (−0.95, 0.16), p = 0.167].”
Quoted verbatim from Integrative evidence construction for resveratrol treatment of nonalcoholic fatty liver disease: preclinical and clinical meta-analyses..
Study

meta-analysis
Dose

300-3,000 mg/day, 8-24 weeks, pooled across trials
Population

adults with NAFLD, resveratrol vs placebo, 5 pooled clinical RCTs
Effect -0.39 standardised mean difference, 95% CI -0.95 to 0.16
Integrative evidence construction for resveratrol treatment of nonalcoholic fatty liver disease: preclinical and clinical meta-analyses.2023PMID:37767399Permalink
berberine — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull resultreplicated ×1
“The effect of BBR supplementation on AST was non-significant (WMD = −2.94; 95%CI, −8.68 to 2.81; P = 0.316).”
Quoted verbatim from The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis..
Study

meta-analysis
Population

Adults in randomised controlled trials of berberine (nine effect sizes pooled)
Effect -2.94 mean difference, 95% CI -8.68 to 2.81
The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis.2022PMID:36313096Permalink
NMN zwitterion — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result
“NMN supplementation did not significantly alter AST levels: MD = −0.24 U/L, 95% CI −1.43 to 0.94, p = 0.686, I2 = 0%.”
Quoted verbatim from Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis..
Study

meta-analysis
Dose

250-2000 mg/day oral across included trials
Population

Adults in randomized controlled trials of oral NMN or NMN-related preparations (including MIB-626) against placebo or no-NMN controls; random-effects pooled analysis of 10 comparisons
Effect -0.24 mean difference, 95% CI -1.43 to 0.94
Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis.2026PMID:42514320Permalink
curcumin — no detected effect on
LimitedEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.FindingNull result
“A comparison of aspartate transaminase, alanine transaminase, and creatinine levels revealed no significant differences between the curcumin and placebo groups.”
Quoted verbatim from Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial..
Study

RCT
Dose

1500 mg/day curcuminoid extract
Population

obese adults with type 2 diabetes mellitus, safety assessment
Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.2025PMID:41096556Industry fundedPermalink
berberine — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×1
“However, berberine intake did not affect liver enzymes, including alanine aminotransferase (ALT) (WMD = -1.66 I/U, 95% CI -3.98, 0.65, P = 0.160) and aspartate aminotransferase (AST) (WMD = -0.87 I/U, 95% CI -2.56, 0.82, P = 0.311).”
Quoted verbatim from The effect of berberine supplementation on obesity parameters, inflammation and liver function enzymes: A systematic review and meta-analysis of randomized controlled trials..
Study

meta-analysis
Population

adults with obesity or metabolic disorders; meta-analysis of 12 RCTs
The effect of berberine supplementation on obesity parameters, inflammation and liver function enzymes: A systematic review and meta-analysis of randomized controlled trials.2020PMID:32690176Permalink

Show the remaining 1

L-glutamine — no detected effect on
InsufficientEvidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited.FindingNull result
“Likewise ALT and AST were not modified by glutamine supplementation (Table 3).”
Quoted verbatim from Long-term intermittent glutamine supplementation repairs intestinal damage (structure and functional mass) with advanced age: assessment with plasma citrulline in a rodent model..
Study

animal · not in humans
Dose

glutamine in drinking water 7 consecutive days a month for 10 months, 20% of dietary protein (about 0.8 g/rat/day)
Population

Very old (27-month) female Wistar rats given intermittent oral glutamine for 10 months versus water-only controls
Long-term intermittent glutamine supplementation repairs intestinal damage (structure and functional mass) with advanced age: assessment with plasma citrulline in a rodent model.2014PMID:25389959Permalink

How it is measured

Serum aspartate aminotransferase catalytic activity by clinical enzymatic assay.

Measured, not recorded

Subject: aspartate aminotransferase
Measurements: 8 measurements
Recorded as a finding: No

Show what was measured

Aspartate aminotransferase
no effect, p = 0.311
aspartate aminotransferase (AST) (WMD = -0.87 I/U, 95% CI -2.56, 0.82, P = 0.311)
PMID:32690176 · one of two readings recorded this
aspartate aminotransferase
no effect, p = 0.58
AST (WMD: -0.44 mg/dl; 95% CI: -2.02 to 1.14, P = 0.58)
PMID:35623810 · one of two readings recorded this
Aspartate aminotransferase
n = 43
AST | Control | 43 | 33.0000 | 19.67837 | 1.28125 | 0.893 | 0.280 | 73 | 43 | 43.7209 | 21.20122 | 0.81468 | 0.407 | 0.140 | 73
PMID:35997951 · one of two readings recorded this
Aspartate aminotransferase
n = 32
Intervention | 32 | 31.7188 | 19.48073 | 1.28125 | 32 | 42.9063 | 29.37341 | 0.81468
PMID:35997951 · one of two readings recorded this
Aspartate aminotransferase
no effect, p = 0.119, n = 51
AST (SGOT) | 52.88 (46.50) | 31.75 (30.20) | 0.020 | −21.13 (8.46) | 55.54 (59.06) | 44.74 (29.07) | 0.349 | −10.80 (11.33) | 0.119
PMID:36597167 · one of two readings recorded this
Aspartate aminotransferase
increases, p = 0.044
but increased AST levels significantly (WMD: 2.54 IU/L; 95%CI: 0.06 to 5.01; P = 0.044)
PMID:37794481 · one of two readings recorded this
aspartate aminotransferase
increases
aspartate aminotransferase increased only in the niacin and control groups
PMID:38281653 · one of two readings recorded this
aspartate aminotransferase
decreases
Aspartate aminotransferase and alanine aminotransferase levels decreased, accompanied by lower values of C-reactive protein and erythrocyte sedimentation rate
PMID:42282227 · one of two readings recorded this

Sources cited

25 papers

Subject: aspartate aminotransferase
Findings: 25
Papers: 25

Compound

Direction

Findings

Strongest evidence

down 7 · no effect 1

no effect 2 · down 1

no effect 1 · down 1

no effect

down

no effect

down

down 1 · no effect 1

down

Lactobacillus acidophilus

down

Moringa oleifera

down

sodium benzoate

Measured, not recorded

Subject

aspartate aminotransferase

Measurements

8 measurements

Recorded as a finding

Show what was measured

Aspartate aminotransferase
no effect, p = 0.311
aspartate aminotransferase (AST) (WMD = -0.87 I/U, 95% CI -2.56, 0.82, P = 0.311)
PMID:32690176 · one of two readings recorded this
aspartate aminotransferase
no effect, p = 0.58
AST (WMD: -0.44 mg/dl; 95% CI: -2.02 to 1.14, P = 0.58)
PMID:35623810 · one of two readings recorded this
Aspartate aminotransferase
n = 43
AST | Control | 43 | 33.0000 | 19.67837 | 1.28125 | 0.893 | 0.280 | 73 | 43 | 43.7209 | 21.20122 | 0.81468 | 0.407 | 0.140 | 73
PMID:35997951 · one of two readings recorded this
Aspartate aminotransferase
n = 32
Intervention | 32 | 31.7188 | 19.48073 | 1.28125 | 32 | 42.9063 | 29.37341 | 0.81468
PMID:35997951 · one of two readings recorded this
Aspartate aminotransferase
no effect, p = 0.119, n = 51
AST (SGOT) | 52.88 (46.50) | 31.75 (30.20) | 0.020 | −21.13 (8.46) | 55.54 (59.06) | 44.74 (29.07) | 0.349 | −10.80 (11.33) | 0.119
PMID:36597167 · one of two readings recorded this
Aspartate aminotransferase
increases, p = 0.044
but increased AST levels significantly (WMD: 2.54 IU/L; 95%CI: 0.06 to 5.01; P = 0.044)
PMID:37794481 · one of two readings recorded this
aspartate aminotransferase
increases
aspartate aminotransferase increased only in the niacin and control groups
PMID:38281653 · one of two readings recorded this
aspartate aminotransferase
decreases
Aspartate aminotransferase and alanine aminotransferase levels decreased, accompanied by lower values of C-reactive protein and erythrocyte sedimentation rate
PMID:42282227 · one of two readings recorded this